Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.
Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Overall survival at 5 years was 100% with the reduced-intensity conditioning regimen compared with 48.5% with the myeloablative conditioning regimen.
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Progression-free survival was superior with lenalidomide compared with placebo, while health-related quality of life was similar and did not change during the study.
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Researchers characterized outcomes for enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, and peripheral gamma delta T-cell lymphoma.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
The combination warrants no further study in these patients.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Significant associations were found between primary central nervous system lymphoma and systemic lupus erythematosus, myasthenia gravis, and uveitis.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.